Clinical Trial

A Study of Simmitinib Plus Irinotecan in Advanced Esophageal Squamous Cell Carcinoma

Unknown Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated July 22, 2024 (before its estimated January 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
To evaluate the safety and efficacy of simmitinib plus irinotecan liposome in the treatment of advanced esophageal squamous cell carcinoma, and to evaluate the PK of the drug and the correlation between biomarkers and clinical efficacy of simmitinib plus irinotecan liposome.
Protocol Amendment History 1 change
critical Trial status changed: Recruiting → Unknown 2026-08-02
Trial Details
NCT Number NCT06512428
Lead Sponsor Shanghai Runshi Pharmaceutical Technology Co., Ltd
Conditions Advanced Esophageal Squamous Cell Carcinoma
Enrollment 138 participants
Start Date 2024-03-15
Primary Completion 2026-01-30 (estimated)
Study Completion 2026-01-30 (estimated)
Updated on ClinicalTrials.gov 2024-07-22